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A B S T R A C T
Background: Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4–6 weeks
(20–30 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Dis-
order in adults who have not responded to prior antidepressant medications. In 2011, leading TMS clinical
providers and researchers created the Clinical TMS Society (cTMSs) (www.clinicaltmssociety.org, Green-
wich, CT, USA), incorporated in 2013.
Methods: This consensus review was written by cTMSs leaders, informed by membership polls, and ap-
proved by the governing board. It summarizes current evidence for the safety and eﬃcacy of the use of
TMS therapy for treating depression in routine clinical practice. Authors systematically reviewed the pub-
lished TMS antidepressant therapy clinical trials. Studies were then assessed and graded on their strength
of evidence using the Levels of Evidence framework published by the University of Oxford Centre for
Evidence Based Medicine. The authors then summarize essentials for using TMS therapy in routine clin-
ical practice settings derived from discussions and polls of cTMSs members. Finally, each summary clinical
recommendation is presented with the substantiating peer-reviewed, published evidence supporting that
recommendation. When the current published clinical trial evidence was insuﬃcient or incomplete, expert
opinion was included when suﬃcient consensus was available from experienced clinician users among
the membership of the cTMSs, who were polled at the Annual Meetings in 2014 and 2015.
Conclusions: Daily left prefrontal TMS has substantial evidence of eﬃcacy and safety for treating the acute
phase of depression in patients who are treatment resistant or intolerant. Following the clinical recom-
mendations in this document should result in continued safe and effective use of this exciting new treatment
modality.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
TMS therapy uses a computerized, electromechanical medical
device toproduceanddelivernon-invasive,magnetic stimulationusing
brief duration, rapidly alternating, or pulsed,magnetic ﬁelds to induce
electrical currents directed at spatially discrete regions of the cere-
bral cortex. Thismethod of cortical stimulation by application of brief
magnetic pulses to the head is known as transcranialmagnetic stim-
ulation or TMS. When pulses of TMS are delivered repetitively, this
is called repetitive TMS, or rTMS. These pulses can be delivered at
either high (10–20 Hz) or low frequency (less than or equal to 1 Hz)
[1]. Most clinical TMS treatments delivered for treating depression
are typically given at 10 Hz to 18 Hz [2,3]. The peak magnetic ﬁeld
strength achieved with each pulse is approximately 1.5 Tesla, right
underneath the coil, similar in strength to the magnetic ﬁeld pro-
duced by a typical magnetic resonance imaging (MRI) device [4,5].
TheMRI ﬁeld is large (ﬁllingmuch of the room) and is constantly on.
TMSmagnetic ﬁelds are focal and brief [5]. In 2008, theUnited States
Food and Drug Administration (FDA) cleared the ﬁrst TMS device for
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therapeuticclinicaluse inMajorDepressiveDisorder (MDD).Thisdevice
was a focal iron core coil produced by Neuronetics Inc. (Malvern, PA,
USA). In 2013, the FDA cleared a second device (i.e. the H-Coil) pro-
ducedbyBrainsway (Jerusalem, Israel). In2015, twoadditional devices
were FDA cleared, the Magstim Company’s (Wales, UK) ﬁgure eight
coil and Tonica’s (Magventure) ﬁgure eight coil. Product manufac-
turer manuals provide technical details about each coil and system,
which are beyond the scope of this review.
Methods: literature review
Peer reviewed literature on TMS therapy was obtained by search-
ing the publicly accessible literature databases available on PubMed
(http://www.ncbi.nlm.nih.gov/pubmed). Additional searches were
performed on the ClinicalTrials.govwebsite (http://www.clinicaltrials
.gov/). Searches used the terms Brainsway, H-coil, rTMS, NeuroStar,
Neuronetics, Magstim, Magventure transcranial magnetic stimula-
tion, Deep TMS, major depressive disorder, depression, clinical trials.
The authors reviewed over 100 peer-reviewed publications dealing
with TMS therapy in depression and referenced (see References).
Twenty-three key studies were graded on their strength of evi-
dence (see Table 1). The framework used was the Levels of Evidence
criteria published by the University of Oxford Centre for Evidence
BasedMedicine (http://www.cebm.net/idex.aspx?0=5653) [29]. This
methodology uses evidence on ﬁve major levels, placing the great-
est emphasis on evidence obtained from randomized controlled trials
and prior systematic reviews [30]. Level 5, the lowest level, in-
cludes anecdotal evidence or non-human animal based evidence.
Level 4 includes case series. Level 3 includes systematic reviews or
controlled individual cases. Level 2 includes systematic reviews of
controlled trials. Level 1, the highest level of evidence, includes large,
prospective, positive, randomized controlled trials. In addition to
the literature database search, additional information was re-
quested of the product manufacturers, including any peer-reviewed
scientiﬁc publications. Information publicly available on the manu-
facturers’ website was also reviewed. Finally, the committee
requested and reviewed themanufacturers’ Medical Technology Dos-
siers. This approach is similar to a recent overall TMS guidelines paper
published by a European group of experts [31]. Unlike this guide-
lines document, the European review extensively covers many other
potential clinical uses of TMS (e.g. pain, movement disorders), and
does not present a consensus of practicing clinicians, and is not ex-
clusively focused on using TMS for treating depression.
User survey and consensus: The Clinical TMS Society conducted
a survey on typical clinical TMS practices at its Annual Meeting in
Toronto, Canada, on May 28th 2015. The Clinical Standards and In-
surance committees created the surveywith contributions fromDrs.
Tarique Perera,Max Okasha,Michelle Cochran, and Kevin Kinback. A
total of 68 members representing over 75 TMS practices partici-
pated in the surveyusingPollEverywhere software.Only fullmembers
who were practicing clinicians owning or operating outpatient TMS
clinics were eligible to vote. Although the Clinical TMS society is in-
ternational in scope, it is based in North America. At the time of this
survey, only 9memberswere from outside of North America (13% of
the total). TheUS based practitioners are likely heavily inﬂuenced by
the FDA approval trials. The resultswere tabulated by the society ad-
ministrators and are available as supplementary material.
Results: systematic review of the evidence for (prefrontal, fast
rTMS) TMS therapy
Multi-site randomized controlled trials (RCT)
Three large, multisite, randomized sham-controlled trials in-
cluded an aggregate sample of 703 adult patients with major
depressive disorder (MDD) who had failed between 1 and 4 anti-
depressant trials. [A European multisite trial was not included in
this summary because it involved adjunctive TMS and medica-
tions starting simultaneously, rather than TMS as the primary
treatment or monotherapy [32].] Two of the studies were industry-
sponsored registration trials that led to FDA clearance for the
NeuroStar TMS Therapy System in 2008 [6] and the Brainsway Deep
TMS device in 2013 [8]. The third study was a National Institute of
Mental Health (NIMH)-sponsored, multicenter study, which pro-
vided critical, industry-independent evidence of TMS effects on
depression [7]. This NIMH trial also used an active, sham-controlled
condition [33] and the primary outcome focused on the clinically
important endpoint of remission [34]. All three trials were consis-
tent in their evidence, establishing a statistically signiﬁcant and
clinically relevant beneﬁt with TMS therapy compared to the sham
condition. Furthermore, the safety of Neuronetics TMS Therapy and
Brainsway Deep TMS was aﬃrmed in these three studies, consis-
tent with the earlier scientiﬁc literature.
Neuronetics trial
The ﬁrst randomized, sham-controlled multicenter trial re-
ported in O’Reardon et al. (2007) was conducted globally at 23 sites
(20 in the US, 2 in Australia and 1 in Canada) [6]. Patients met DSM-
IV criteria for MDD, were antidepressant medication free, and
presented with a moderate level of treatment resistance. The study
consisted of several phases: a one week no-treatment lead-in; a four
to six week randomized, sham-controlled acute treatment phase of
daily (weekday) TMS monotherapy; a four to six week open-label
trial in non-responders during the randomized phase; and in re-
sponders, a three week taper phase during which patients began
an open-label, single antidepressant medication and were then fol-
lowed for six months to examine the durability of TMS’s acute effect.
Stimulation parameters were 120%motor threshold (MT), 10 Hz fre-
quency, train duration of 4 s, inter-train interval of 26 s and 75 trains
per session, leading to a total of 3000 pulses over 37.5 min. In the
initial controlled trial phase, patients randomized to active TMS dem-
onstrated a clinically meaningful improvement on the primary
outcomemeasure, baseline to endpoint change on theMontgomery–
Asberg Depression Rating Scale at four weeks (MADRS, p = 0.06,
standardized effect size = 0.39) compared to those patients ran-
domized to sham TMS. Furthermore, an analysis of the one prior
antidepressant failure subsample (n = 164) indicated an even more
robust beneﬁt for TMS versus the sham procedure (p < 0.001).
National Institute of Mental Health (NIMH) trial (optimization of
TMS, OPT-TMS)
The second, multisite, randomized sham-controlled trial pro-
vided industry-independent evidence for the safety and eﬃcacy of
TMS in patients diagnosed with treatment resistant or treatment
intolerant MDD [7]. This study also used the clinical trial version
of the NeuroStar TMS Therapy System (Neuronetics Model 2100 Clin-
ical Research System) and a similar location and the same parameters
as in the Neuronetics trial (left DLPFC, 10 Hz, 120%MT, 3000 pulses).
The trial at four US universities included 190 antidepressant
medication-free outpatients withMDD and an overall moderate level
of treatment resistance (similar to the inclusion and exclusion cri-
teria for patients studied in the industry trial). The investigators
focused on the primary eﬃcacy endpoint of remission based on the
24-item Hamilton Depression Rating Scale (HAMD24). Moreover,
this trial used an active sham method that fully blinded patients,
treaters and raters [33,35]. The trial design consisted of a 2 week
no treatment lead-in phase; a 3-week ﬁxed treatment phase; and
a variable 3-week treatment extension for initial clinical improv-
ers. For the entire population, there was a signiﬁcant effect of active
treatment on the proportion of remitters at the end of the acute
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Table 1
Summary of published studies for the TMS antidepressant studies: study type and grading of strength of evidence.
Study citation (chronological listing within category) Study type Sample size Level of evidence Comments
O’Reardon J.P., Solvason H.B., Janicak P.G., Sampson S., Isenberg K.E., Nahas Z., McDonald
W.M., Avery D., Fitzgerald P.B., Loo C., Demitrack M.A., George M.S., Sackeim H.A. Eﬃcacy
and safety of transcranial magnetic stimulation in the acute treatment of major
depression: a multisite randomized controlled trial. Biol Psychiatry 2007;62:1208–16 [6].
RCT TMS (N = 155)
Sham (N = 146)
Level 1b – individual
RCT
Unique multisite RCT, sponsored by industry (Neuronetics Inc)
Basis of initial FDA clearance for TMS device
George M.S., Lisanby S.H., Avery D., McDonald W.M., Durkalski V., Pavlicova M., Anderson
B., Nahas Z., Bulow P., Zarkowski P., Holtzheimer P., Schwartz T., Sackeim H.A. Daily left
prefrontal transcranial magnetic stimulation therapy for major depressive disorder:
a sham-controlled randomized trial. Arch Gen Psychiatry 2010;67(5):507–16 [7].
RCT TMS (N = 92)
Sham (N = 98)
Level 1b – individual
RCT
Unique multisite RCT, sponsored by US federal NIMH
Independent of industry
Levkovitz Y., Isserles M., Padberg F., Lisanby S.H., Bystritsky A., Xia G., Tendler A.,
Daskalakis Z.J., Winston J.L., Dannon P., Hafez H.M., Reti I.M., Morales O.G., Schlaepfer T.E.,
Hollander E., Berman J.A., Husain M.M., Sofer U., Stein A., Adler S., Deutsch L., Deutsch F.,
Roth Y., George M.S., Zangen A. Eﬃcacy and safety of deep transcranial magnetic
stimulation for major depression: a prospective multicenter randomized controlled trial.
World Psychiatry 2015;14(1):64–73. [8].
RCT TMS (N = 101)
Sham (N = 111)
Level 1b – individual
RCT
Unique multisite RCT, sponsored by industry (Brainsway)
Basis of FDA clearance for Deep TMS device
Avery D.H., Isenberg K.E., Sampson S.M., Janicak P.G., Lisanby S.H., Maixner D.F., Loo C.,
Thase M.E., Demitrack M.A., George M.S. Transcranial magnetic stimulation in the acute
treatment of major depressive disorder: clinical response in an open-label extension trial.
J Clin Psychiatry 2008;69(3):441–51 [9].
OL TMS (N = 158) Level 2b – individual
OL study
Open label follow-on acute eﬃcacy and safety study of subset
cohort from O’Reardon et al. [6]
Demitrack M.A., Thase M.E. Clinical signiﬁcance of transcranial magnetic stimulation
(TMS) in the treatment of pharmacoresistant depression: synthesis of recent data.
Psychopharmacol Bull 2009;42(2):5–38 [10].
RCT TMS (N = 88)
Sham (N = 76)
Level 1b – individual
RCT
RCT subset analysis of ATHF = 1 cohort from O’Reardon et al. [6]
Lisanby S.H., Husain M.M., Rosenquist P.B., Maixner D., Gutierrez R., Krystal A., Gilmer W.,
Marangell L., Aaronson S., Daskalakis Z.J., Canterbury R., Richelson E., Sackeim H.A., George
M.S. Transcranial Magnetic Stimulation (TMS) in the acute treatment of major depression:
clinical predictors of outcome in a multisite, randomized controlled clinical trial.
Neuropsychopharmacology 2009;34:522–34 [11].
RCT TMS (N = 155)
Sham (N = 146)
Level 1b – individual
RCT
RCT subset analysis of predictors of outcome during acute
treatment from O’Reardon et al. [6]
Janicak P.G., O’Reardon J.P., Sampson S.M., Husain M.M., Lisanby S.H., Rado J.T., Demitrack
M.A. Transcranial Magnetic Stimulation (TMS) in the treatment of major depressive
disorder: a comprehensive summary of safety experience from acute exposure, extended
exposure, and during reintroduction treatment. J Clin Psychiatry 2008;69(2):222–32 [12].
RCT TMS (N = 165)
Sham (N = 160)
Level 1b – individual
RCT (safety)
Comprehensive safety and tolerability analysis of population
included in O’Reardon et al. [6]
Includes 6 month longer term follow up phase
Carpenter L.L., Janicak P.G., Aaronson S.T., Boyadjis T., Brock D.G., Cook I.A., Dunner D.L.,
Lanocha K., Solvason H.B., Demitrack M.A. Transcranial magnetic stimulation (TMS) for
major depression: a multisite, naturalistic, observational study of acute treatment
outcomes in clinical practice. Depress Anxiety 2012;29(7):587–96 [13].
Cohort TMS (N = 307) Level 2b – individual
cohort study
Unique, cohort study of patients treated in routine, real-world
clinical practice settings in the United States
Janicak P.G., Dunner D.L., Aaronson S.T., Carpenter L.L., Boyadjis T.A., Brock D.G., Cook I.A.,
Lanocha K., Solvason H.B., Bonneh-Barkay D., Demitrack M.A. Transcranial Magnetic
Stimulation (TMS) for major depression: a multisite, naturalistic, observational study of
quality of life outcome measures in clinical practice. CNS Spectr 2013;18:322–32 [14].
Cohort TMS (N = 307) Level 2b – individual
cohort study
Cohort study of patients treated in routine, real-world clinical
practice settings in the United States
Quality of life outcomes based on Carpenter et al. [13]
McDonald W.M., Durkalski V., Ball E.R., Holtzheimer P.E., Pavlicova M., Lisanby S.H., Avery
D., Anderson B.S., Nahas Z., Zarkowski P., Sackeim H.A., George M.S. Improving the
antidepressant eﬃcacy of transcranial magnetic stimulation: maximizing the number of
stimulations and treatment location in treatment-resistant depression. Depress Anxiety
2011;28(11):973–80 [15].
OL TMS (N = 141) Level 2b – individual
OL study
Open label follow-on acute eﬃcacy and safety study of subset
cohort from George et al. [7]
Janicak P.G., Nahas Z., Lisanby S.H., Solvason H.B., Sampson S.M., McDonald W.M.,
Marangell L.B., Rosenquist P.B., McCall W.V., Kimball J., O’Reardon J., Loo C., Husain M.H.,
Krystal A., Gilmer W., Dowd S.M., Demitrack M.A., Schatzberg A.F. Durability of clinical
beneﬁt with transcranial magnetic stimulation (TMS) in the treatment of
pharmacoresistant major depression: assessment of relapse during a 6-month, multisite,
open-label study. Brain Stimul 2010;3:187–99 [16].
OL TMS (N = 99)
Sham (N = 21)
Level 2b – individual
OL study
Open label follow-on long term eﬃcacy study of subset cohort
from O’Reardon et al. [6]
Mantovani A., Pavlicova M., Avery D., Nahas Z., McDonald W.M., Wajdik C.D., Holtzheimer
P.E., George M.S., Sackeim H.A., Lisanby S.H. Long-term eﬃcacy of repeated daily
prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression.
Depress Anxiety 2012;29:883–90 [17].
OL TMS (N = 50) Level 2b – individual
OL study
Open label follow-on long term eﬃcacy study of subset cohort
from George et al. [7]
(continued on next page)
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Table 1 (continued)
Study citation (chronological listing within category) Study type Sample size Level of evidence Comments
Levkovitz Y., Harel E.V., Roth Y., Braw Y., Most D., Katz L.N., Sheer A., Gersner R., Zangen A.
Deep transcranial magnetic stimulation over the prefrontal cortex: evaluation of
antidepressant and cognitive effects in depressive patients. Brain Stimul 2009;2:188–200
[18].
RCT TMS (N = 65) Level 2b – randomized
feasibility study
Feasibility eﬃcacy study randomized groups between various
deep TMS coils and in intensities
Isserles M., Rosenberg O., Dannon P., Levkovitz Y., Kotler M., Deutsch F., Lerer B., Zangen A.
Cognitive-emotional reactivation during deep transcranial magnetic stimulation over the
prefrontal cortex of depressive patients affects antidepressant outcome. J Affect Disord
2011;128:235–42 [19].
OL TMS (N = 57) Level 2b – individual
OL study
Open label eﬃcacy study of deep TMS as add on to antidepressant
medications
Harel E.V., Rabany L., Deutsch L., Bloch Y., Zangen A., Levkovitz Y. H-coil repetitive
transcranial magnetic stimulation for treatment resistant major depressive disorder: an
18-week continuation safety and feasibility study. World J Biol Psychiatry 2014;15:298–
306 [20].
OL TMS (N = 29) Level 2b – individual
OL study
Open label long term eﬃcacy study of deep TMS
Rosenquist P.B., Krystal A., Heart K.L., Demitrack M.A., McCall W.V. Left dorsolateral
prefrontal transcranial magnetic stimulation (TMS): sleep factor changes during
treatment in patients with pharmacoresistant major depressive disorder. Psychiatry Res
2013;205(1–2):67–73 [21].
RCT TMS (N = 155)
Sham (N = 146)
Level 1b – individual
RCT
RCT subset analysis of sleep outcomes from O’Reardon et al. [6]
Simpson K.N., Welch M.J., Kozel F.A., Demitrack M.A., Nahas Z. Cost-effectiveness of
transcranial magnetic stimulation in the treatment of major depression: a health
economics analysis. Adv Ther 2009;26(3):346–68 [22].
RCT TMS (N = 155)
Sham (N = 146)
Level 2b – economic/
decision analysis
study
Health economic decision analysis study based on data from
O’Reardon et al. [6]
Comparative health economic cost analysis with next-choice
pharmacotherapy
Agency for Healthcare Research and Quality, Effective Health Care Program, Comparative
Effectiveness Review Number 33, “Nonpharmacologic Interventions for Treatment-
Resistant Depression in Adults”. 2012
SR Total active
TMS sample
examined for
SR (N = 497)
Includes TMS
study data:
(N = 247)
Level 1a – systematic
review
Independent, US government funded systematic review
Allan C.L., Herrmann L.L., Ebmeier K.P. Transcranial magnetic stimulation in the
management of mood disorders. Neuropsychobiology 2011;64:163–9 [23].
SR Total sample
for SR
(N = 1531)
Level 1a – systematic
review (with minor
heterogeneity)
Independent, academic-based systematic review
Modest, clinically non-signiﬁcant heterogeneity in outcome
reported
Schutter D.J. Antidepressant eﬃcacy of high-frequency transcranial magnetic stimulation
over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs:
a meta-analysis. Psychol Med 2009;39:65–75 [24].
SR Total sample
for SR
(N = 1164)
Level 1a – systematic
review
Independent, academic-based systematic review
Slotema C.W., Blom J.D., Hoek H.W., Sommer I.E. Should we expand the toolbox of
psychiatric treatment methods to include repetitive transcranial magnetic stimulation
(rTMS)? A meta-analysis of the eﬃcacy of rTMS in psychiatric disorders. J Clin Psychiatry
2010;71(7):873–84 [25].
SR Total sample
for SR
(N = 1383)
Level 1a – systematic
review
Independent, academic-based systematic review
Berlim M.T., van den Eynde F., Tovar-Perdomo S., Daskalakis Z.J. Response, remission and
drop-out rates following high-frequency repetitive transcranial magnetic stimulation
(rTMS) for treating major depression: a systematic review and meta-analysis of
randomized, double-blind and sham-controlled trials. Psychol Med 2014;44(2):225–39
[26].
SR Total sample
for SR
(N = 1371)
Level 1a – systematic
review
Independent, academic-based systematic review
Solvason H.B., Husain M., Fitzgerald P.B., Rosenquist P., McCall W.V., Kimball J., Gilmer W.,
Demitrack M.A., Lisanby S.H. Improvement in quality of life with left prefrontal
transcranial magnetic stimulation in patients with pharmacoresistant major depression:
acute and six month outcomes. Brain Stimul 2014;7:219–25 [27].
SR Level 1b – systematic
review
Independent, academic-based systematic review
Dunner D.L., Aaronson S.T., Sackeim H.A., Janicak P.G., Carpenter L.L., Boyadjis T., Brock
D.G., Bonneh-Barkay D., Cook I.A., Lanocha K., Solvason H.B., Demitrack M.A. A multisite,
naturalistic, observational study of transcranial magnetic stimulation for patients with
pharmacoresistant major depressive disorder: durability of beneﬁt over a 1-year follow-
up period. J Clin Psychiatry 2014;75(12):1394–401 [28].
Cohort Level 2b – individual
cohort study
Cohort study of patients treated in routine, real-world clinical
practice settings in the United States
Study type (RCT = randomized, controlled trial; OL = open-label trial; Cohort = observational cohort study; SR = systematic review).
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phase (15% active TMS vs. 4% sham control group, p < 0.01), repre-
senting a 4.2 greater odds of reaching remission with active TMS
compared with the sham control group. The authors concluded that
“. . .daily left prefrontal TMS as monotherapy produced signiﬁcant
and clinically meaningful antidepressant therapeutic effects greater
than sham. . ..”
Brainsway trial
In this study involving 20 enrolling sites (13 in US, 1 in Canada,
2 in Europe and 4 in Israel), patients with MDD who had failed 1–4
antidepressant treatment trials during the current episode were en-
rolled and randomized to receive either active Deep TMS (H-coil)
or a sham coil [8]. The trial used an active sham method that fully
blinded patients, treaters and raters. All patients were tapered off
antidepressant medications and received monotherapy Deep TMS
or sham a coil. Of the ITT sample of 212 patients, 181 patients com-
pleted the study, with equivalent rates of dropouts with active and
sham treatment. The acute treatment phase was 5 sessions per week
for 4 weeks, followed by a continuation phase of twice-weekly treat-
ment for an additional 12 weeks. The stimulation site was the left
DLPFC, but the H-coil also likely stimulates more broadly and deeper
than the other ﬁgure eight coils [5,36]. Stimulation parameters were
120% MT, 18 Hz frequency, train duration of 2 s, inter-train inter-
val of 20 s and 55 trains per session, leading to a total of 1980 pulses
over 20 min. The primary endpoint was the change score on the
HAMD21 at week 5, which favored the active versus sham proce-
dure (i.e. 6.39 point improvement active versus 3.11 points sham,
p < 0.001). At week 5, the response rates were 38.4% for Deep TMS
versus 21.4% for sham treatment (p = 0.014). Remission rates were
32.6% for TMS versus 14.6% for sham treatment (p < 0.01). At week
16, the response rates were 44.3% for TMS versus 25.6% for sham
treatment (p < 0.01). Remission rates were 31.8% for Deep TMS versus
22.2% for sham treatment (p = 0.15).
Durability studies
The durability of TMS following the acute course has been dem-
onstrated in several studies both with and without maintenance
antidepressants. Durability studies struggle with a selection bias since
with patients lost to follow up, it is unclear if they are well and no
longer need treatment, or if they have worsened and started other
treatments. Speciﬁcally, the NeuroStar TMS Therapy System’s re-
search version was studied in two independent cohorts: 50 patients
for 3 months [17] and 99 patients for 6 months [16]. A separate,
12-month, follow-up report of 257 patients was reported in an ob-
servational, outcome study [28].
In the ﬁrst durability study, patients who partially responded to
acute TMS (i.e. 25% decrease from the baseline HAMD17) in the
sham-controlled or open-label extension of the Neuronetics-
sponsored multicenter trial [6] were tapered off TMS, started on
maintenance antidepressant monotherapy, and enrolled in a 24-
week naturalistic follow-up study [16]. Over this 6-month period,
10 of 99 (10%; Kaplan–Meier survival estimate = 12.9%) patients re-
lapsed within a mean time of ~23.5 weeks. Among the rest, 38
(38.4%) patients met criteria for symptom worsening and 32/38
(84.2%) re-achieved symptomatic beneﬁts with adjunctive TMS.
Overall, at 6 months, 75% maintained full response and 50% main-
tained remission based on either the MADRS or HAMD24 scores.
This same cohort of 99 responders displayed signiﬁcant improve-
ment in both functional status and Quality of Life (QOL) outcomes
and was observed immediately after the completion of TMS and at
6-months follow up [27]. Similar rates of durability were seen in a
separate 3-month follow up to the NIMH OPT-TMS study in remit-
ters to an acute double-blind sham controlled trial of TMS (n = 18),
or an open-label extension in patients who did not respond to the
acute trial (n = 43) [17]. Of 61 remitters, 37 attended the follow up
assessments at 3-months at which 5 had relapsed (relapse
rate = 13.5%) based on HAMD criteria over an average time of 7.2
weeks, but 4 regained remission by the end of the study. These re-
mitters had been started back on maintenance antidepressant
medication. Additionally, in a 1-year, multisite, naturalistic, obser-
vational study conducted in 120 patients who met criteria for
response or remission after their acute TMS course, 62% contin-
ued to meet response criteria 12 months later [28]. The results of
these studies in patients placed back on antidepressant medica-
tions demonstrate high (i.e. 64–90%) durability for acute TMS beneﬁts
over a 3–12 month period, with a majority of patients who re-
lapsed responding to additional TMS sessions.
Continuation/maintenance studies
When TMS is used for the treatment of an acute episode, it is
reasonable to consider continuation TMS (C-TMS) or maintenance
(M-TMS) to prevent relapse of the current episode or recurrence of
a new episode. The term ‘continuation TMS’ (C-TMS) and ‘mainte-
nance TMS’ (M-TMS) are frequently used interchangeably and
indiscriminately across the mood disorder treatment continuum.
For the purpose of this report, we will use the following deﬁni-
tions: an index/acute course is the initial series of treatments given
to relieve acute symptoms of the illness. C-TMS is a course that begins
after the index course, lasts up to 6 months and is designed to
prevent relapse of the episode (return of the symptoms to full
syndromal criteria before the end of the natural duration of the
illness). M-TMS is a course that begins after the end of C-TMS and
is intended to prevent recurrence of an episode (a new episode).
The only published controlled trial to date of continuation TMS was
performed in the Brainswaymulticenter trial. MDD patients (N = 212)
were randomized to sham or active TMS during the acute 4-week
treatment phase followed by a continuation phase of 2 treat-
ments a week for an additional 12 weeks [8]. At the end of the
continuation phase (week 16), the difference in response rates
between Deep TMS (44.3%) and the sham group (25.6%) was sig-
niﬁcant (p < 0.001) but the remission rates between TMS (31.8%) and
sham (22.2%) were not signiﬁcant (p = 0.15). The majority of pa-
tients who achieved remission after acute treatment (32.6% in the
Deep TMS and 14.6% in the sham group) did not relapse (i.e.
HAMD21 > 17) during the 12-week continuation phase.
In a feasibility study, Harel and colleagues studied 29 MDD pa-
tients who did not respond to at least one antidepressant medication
or who did not tolerate at least two medication trials. They were
treated with the Brainsway H1 coil as an add-on to medications and
treated in an acute phase with 5 sessions per week for 4-weeks, fol-
lowed by a C-TMS phase for 8 weeks, at 2 sessions per week and
then for an additional 10-weeks, at one session per week [20]. Re-
sponse at the end of the 4-week acute phase was 46% and 27% met
remission criteria (all remitters are also included as responders).
Response and remission rates after the additional 18 weeks of C-TMS
(at week 22) were both 31% (i.e. all responders also met remission
criteria). Mean improvement in HAMD21 was 9.48 points after 4
weeks and 10.12 points after 22 weeks. The study results indicate
that antidepressant effect is preserved by continuation of Deep TMS
treatment over 18 weeks.
Most recently, Neuronetics sponsored a multi-site study involv-
ing 49 antidepressant free treatment resistant depressed patients
who responded or remitted to a 6-week acute course of treat-
ment. Subjects were randomized to receive one TMS treatment
session per month, regardless of symptoms, or to bemonitored. Both
groups received rescue TMS if their symptoms worsened. There was
a mathematical difference in favor of scheduled TMS in terms of de-
laying time to relapse, although this was not statistically signiﬁcant.
There was a high rate of re-response to TMS if it was needed again
(78%) [37].
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Naturalistic outcomes study in community practices
Neuronetics sponsored a naturalistic, multisite, clinical out-
comes study (Clinicaltrials.gov listing: NCT001114477) evaluating
the effectiveness of the NeuroStar TMS Therapy System in routine
clinical practice [13,14]. In these studies, 307 MDD patients under-
going open label TMS showed statistically signiﬁcant improvement
in functional status on a broad range of global, mental health and
physical health domains.
Meta-analyses
There are over 15 meta-analyses and numerous systematic
reviews of TMS for depression. Among these, ﬁve of the more recent
meta-analyses included the results of one or both of the acute TMS
therapy, randomized, controlled trials using the Neuronetics’ re-
search device in their synthesis of the evidence supporting TMS for
depression (Agency for Healthcare Research and Quality, 2012)
[23,38–43]; see Table 1). These analyses are consistent in their con-
clusions, reporting that the sham-controlled evidence base for the
use of TMS in depression is clinically and statistically signiﬁcant.
Society endorsements
TMS for the treatment of depression has also received positive
endorsements by specialty societies and technology assessment en-
tities, including the American Psychiatric Association [44], theWorld
Federation of Societies for Biological Psychiatry [45], the Canadian
Network for Mood and Anxiety Disorders [46], the Royal Australia
and New Zealand College of Psychiatrists (Position Statement #79,
Oct. 2013), and the Agency for Healthcare Research and Quality
(2012) [47].
Thus, TMS is a recognized treatment in routine clinical practice
for patients who have not beneﬁted from treatment with antide-
pressant medications. The American Medical Association has
established three CPT Category I codes for the therapeutic use of
TMS devices. These three codes became available in January 2012
CPT Code Book (AMA CPT Editorial Panel, 2012). The codes are sum-
marized in Table 2 and the reader is referred to the AMA Code Book
for further information.
Overall conclusions and summary of the literature review
Three large, randomized controlled studies support TMS therapy
for 4–6weeks as an effective treatment for patients withMDD (single
or recurrent course of illness) who have not beneﬁtted from prior
antidepressant medication (+/− psychotherapy?). The eﬃcacy and
safety of TMS using a speciﬁc, deﬁned treatment protocol of high-
frequency, left prefrontal TMS was conﬁrmed in two large, multisite,
randomized controlled trials [6,7] (one of which was conducted in-
dependent of industry involvement) [7] and one large, multisite trial
that used Deep TMS [8]. All three studies are consistent in their con-
clusions. These RCT results are also supported by the results of large,
multisite, observational studies of TMS as applied in routine clin-
ical practice settings [13,14,28,48]. Finally, several professional
organizations have included TMS in their guidelines as a recom-
mended acute treatment for major depression.
Recommended clinical practice essentials
The following section highlights some of the essential compo-
nents of good clinical practice with TMS. The information
summarized here is intended to highlight some of the major areas
of interest and is not intended as a substitute for more compre-
hensive device training provided by industry regarding their speciﬁc
TMS machines.
Training
Peer-to-peer and graduate medical education have an impor-
tant role in physician and staff training. In addition to industry-
sponsored training that is device speciﬁc, we recommend that TMS
providers complete additional training either through a university
aﬃliated or industry independent Continuous Medical Education
(CME) program or through additional peer-to-peer direct supervi-
sion. Providers with a strong foundation in TMS through their training
or extensive TMS experience may be exempt from the above rec-
ommendation. It is also recommended that the attending physician
and all staff who are members of the TMS treatment team receive
appropriate product training on the use of the new technology. It
is recommended that at a minimum, the TMS team receive the de-
tailed product training offered by the devicemanufacturer and obtain
written documentation of training.
We also advise that a TMS clinic establish formal standard op-
erating procedures (SOPs) related to training and ongoing criteria
to maintain procedural skills for all staff who are involved in the
delivery of TMS in the oﬃce setting. Documentation of implemen-
tation and adherence to these procedures should be a routine part
of oﬃce practice. The cTMSs can offer recommendations and support
of speciﬁc examples of these practices among its members.
Roles and responsibilities
The attending physician who prescribes a treatment course of
TMS, which involves a medical device, is ultimately responsible for
the overall daily management of the TMS treatment team [49]. We
recommend that the prescribing physician to establish the antici-
pated clinical treatment plan based on assessment of the patient’s
clinical history and review this treatment plan with the patient prior
to beginning the course of treatment. It is suggested that the pre-
scribing physician or another physician in the practice should
perform the initial motor threshold determination and identify the
appropriate coil location for subsequent treatments. However,
conduct and oversight of subsequent daily treatment sessions in-
cluding subsequent motor threshold determinations may be
delegated by the attending physician to another, appropriately qual-
iﬁed member of the clinical staff. In this circumstance, the physician
should be accessible via telephone in the case of an emergency. The
physician should review the clinical course of each daily treat-
ment session to determine whether any modiﬁcations to the
subsequent daily treatment should occur. For example, the physi-
cian should evaluate whether a re-determination of motor threshold
is required and respond to any adverse events as they occur [50].
Conduct and oversight of daily treatment sessions may be del-
egated by the attending physician to another member of the clinical
staff, but should be physician supervised. We recommend that all
TMS clinical staff maintain appropriate training to support their role
as ﬁrst responders to potential medical emergencies.
The society further recommends that the TMS operator have car-
diopulmonary (CPR) or basic life support (BLS) training; and in the
Table 2
CPT I codes for therapeutic transcranial magnetic stimulation.
Code Description
90867 Therapeutic Repetitive Transcranial Magnetic stimulation (TMS)
treatment; initial, including cortical mapping, motor threshold
determination, delivery and management
(Report only once per course of treatment)
(Do not report 90867 in conjunction with 95928, 95929, 90868,
90869)
90868 Subsequent delivery and management, per session
90869 Subsequent motor threshold re-determination with delivery and
management
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US, Health Insurance Portability and Accountability act (HIPAA) com-
petency and compliance. Non-physician operators should also
undergo manufacturers’ training prior to independently perform-
ing treatments. TMS is a medically complex treatment, and therefore
emergency medical services must be accessible at all times. The op-
erator should provide updates, progress notes or both every day that
should be monitored by the prescribing physician. We strongly en-
courage the use of repeated ratings with mood scales to document
depression changes.
Establishing a treatment plan
The standard treatment regimen recommended in the TMS de-
pression clinical development studies involved a speciﬁed parameter
set of high frequency, left prefrontal rTMS that showed gradual and
continued beneﬁt after ﬁve daily treatments over 4–6 weeks. Some
patients who respond slowly to TMS may beneﬁt from 1–4 addi-
tional weeks of treatment [15,17]. The Brainsway study demonstrated
that an additional 12 weeks of twice weekly continuation in-
creased response rates by 8%. Therefore, patients should be advised
of this likely pattern of outcome prior to initiating treatment, in order
to set appropriate expectations of the time course of beneﬁt and
when and how assessment of eﬃcacy should reasonably be
estimated.
Informed consent
Once a decision has been made to prescribe the use of TMS as
a treatment option, it is crucial that the patient has a thorough, ac-
curate, and informative presentation of what a course of TMS will
entail. During the treatment sessions, the patient will be unable to
have free movement of their head and thus have a limited ﬁeld of
view of the operating aspects of the device. As such, reducing anxiety
regarding the nature of the treatment process is essential prior to
starting. A variety of visual aids should be provided with the product
documentation, including brochures and videos, which can be used
to instruct the patient on the treatment process. In many clinical
situations, it is appropriate to invite family members into the con-
sultation room to address any questions they may have. Only when
the procedure is well understood and questions have been an-
swered should written informed consent be obtained and
documented in the medical record.
Safety considerations
A signiﬁcant safety risk associated with TMS is the inadvertent
induction of a seizure [51,52]. Therefore, it is essential that both the
supervising physician and the TMS treatment staff are familiar with
proper ﬁrst responder capability for such an event.
The incidence of seizure with TMS is small and appears slightly
lower than the incident risk reported for the use of current anti-
depressant medications [12]. Adherence to recommendations
endorsed by International Federation for Clinical Neurophysiology
can help minimize this risk [52,53]. In clinical practice, the use of
an appropriately worded informed consent procedure (discussed
in the preceding section) is recommended, as are adequate methods
for pre-treatment clinical screening of potential seizure risk and con-
tinuous clinical monitoring of the TMS treatment session itself. All
clinical personnel involved in the delivery of TMS must be trained
as ﬁrst responders to provide appropriate initial management of a
seizure or other medical event. The overall risk of seizure is esti-
mated to be less than 1 in 30,000 treatment sessions (<0.003%) or
less than 1 in 1000 patient exposures (<0.1%) with the NeuroStar
coil (NeuroStar TMS Therapy UserManual, Neuronetics, Inc., Malvern,
PA, USA) and 6 in 5000 patients with the Brainsway coil (User
Manual, Brainsway, Israel) [54]. All seizures to date have been self-
limited and occurred only during the treatment session. We note
that there are no speciﬁc labeling requirements that advanced re-
suscitative equipment be present in the TMS treatment room. It is
the consensus of the cTMSs that IV access, cardiac deﬁbrillators,
suction, and oxygen are NOT necessary for the safe administration
of TMS in an outpatient TMS oﬃce.
Vasovagal syncope has also occurred with TMS, particularly in
initial sessions. Management here is largely reassurance to the
patient, and protection from harm if they fall.
During a TMS session, the magnetic pulse produces an audible
clicking sound, which varies with different coil designs and inten-
sity [55,56]. Therefore, an additional standard safety precaution for
all TMS treatments is the use of earplugs or other hearing protec-
tion capable of at least 30 dB sound reduction [57]. Such a precaution
eliminates the risk of changes in auditory threshold with treat-
ment for either the patient or the treatment provider. Of note, the
Dhamne review concluded that for short exposure of a session, the
sound pressure level does not exceed Occupational Safety Hazard
permissible thresholds [35].
The TMS treatment can produce scalp discomfort [35,58,59]. This
is location and intensity dependent, and patients generally develop
tolerance to this over the ﬁrst two weeks. As a result, in patients
that are highly sensitive, many clinicians use a gradually escalat-
ing dose of TMS over the ﬁrst week.
Outcome evaluation
We recommend that objective documentation of clinical beneﬁt
be obtained as a routine practice in a TMS service in order to doc-
ument changes and provide data for making clinical decisions. This
is important for ongoing clinical care andmay be required by payers
for insurance approval. Several validated patient-reported outcome
measures of depression symptoms are available in the public domain,
along with their methods of scoring. A majority of cTMSs members
use either the Patient Health Questionnaire, 9-Item scale (PHQ-9;
49; http://www.depression-primarycare.org/clinicians/toolkits/
materials/forms/phq9/), the Inventory of Depression Scale – Self
Rated (IDS-SR) [60] or the Beck Depression Inventory [61].
Post-treatment planning
Once a determination of maximum beneﬁt is made, the TMS
treatments should be tapered and a continuation and then main-
tenance regimen developed for the patient. In the Neuronetics and
OPT-TMS clinical studies, patients were discontinued from treat-
ment slowly over a 3-week interval (3/week, then 2/week, then 1
on the last week), while maintenance antidepressant medications
were started. Following the Neuronetics trial, patients were re-
stricted to a single antidepressant medication only, but were
permitted to re-access to TMS upon symptom re-emergence [16].
Clinical recommendations
Indicated Patient Population: The labeled indication for use for
the TMS therapy states that, “TMS therapy is indicated for the treat-
ment of Major Depressive Disorder in adult patients who have failed
to receive satisfactory improvement from prior antidepressant med-
ication in the current episode.”
In clinical descriptive terms, patients for whom TMS therapy is
indicated demonstrated the following demographic and clinical fea-
tures in the three major published, randomized controlled trials:
Moderate to severe treatment resistance in the current treat-
ment episode – Patients had received 1–4 adequate antidepressant
medication attempts and a range of 1–23 total antidepressant at-
tempts. Among all of these treatment attempts, a patient had
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received at least one antidepressant medication at a research-
grade level of exposure adequacy (i.e. adequate dose and duration)
in order to formally establish evidence of resistance to pharmaco-
logical interventions in the current illness episode. The majority of
clinical TMS society members reported that a “suﬃcient trial” means
one with adequate dose and duration of at least 6–8 weeks and an-
tidepressant failure from an adequate trial or intolerance of
antidepressants provided over a shorter duration.
The OPT-TMS trial and the Brainsway Deep TMS trial also in-
cluded patients who were treatment intolerant (i.e. had tried
antidepressant medications but were unable to receive a full dose
due to emergent side effects). The total lifetime number of antide-
pressant medication treatment exposures was not limited in these
clinical studies.
A recurrent course of illness – More than 95% of patients had
experienced prior illness episodes. The average patient age was ap-
proximately 49 years, constituting an average age about a decade
older than typical for a ﬁrst-episode depression population.
Moderate to severe illness severity (symptoms and functional
disability) at initial clinical evaluation where work productivity re-
ﬂected signiﬁcant functional morbidity. Nearly 50% of patients were
currently unemployed due to their illness and about 30% were re-
ceiving disability due to their current illness.
Based on the published evidence summarized in this clinical
guideline, the cTMSs aﬃrms the following recommendations for the
routine use of TMS in clinical practice. Each recommendation is
graded in a manner that follows the format of the Grades of Rec-
ommendation framework published by the University of Oxford
Centre for Evidence Based Medicine.
Recommendation 1: TMS therapy is recommended as an acute
treatment for symptomatic relief of depression in the indi-
cated patient population.
Statement of speciﬁc recommendation for use: TMS therapy
should be considered in patients who present with a clinical diag-
nosis consistent with DSM-5 deﬁned Major Depressive Disorder,
single or recurrent episode, or equivalent nosology and for
whom antidepressant medication has not provided a satisfactory
clinical beneﬁt, or for whom intolerance to medications precludes
their use. TMS therapy should be administered in a standard pro-
tocol of high-frequency, left prefrontal treatment as speciﬁed in
the product labeling, though other treatment parameters can be
used based on clinical considerations for a speciﬁc patient and the
judgment of the provider. The standard parameter set described
in each product labeling was studied in three Level 1 randomized
controlled trials and provided clinical beneﬁt in treatment courses
up to 6 weeks in duration. Controlled studies of longer duration,
acute treatment courses or using alternative treatment param-
eters are not established.
Strength of the recommendation: A, consistent evidence from
Level 1 studies
Principal Supporting Evidence: O’Reardon et al. [6] [Level 1b –
Individual RCT]; George et al. [7] [Level 1b – Individual RCT];
Levkovitz et al. [8] [Level 1b – Individual RCT]
Additional Expert Consensus Comments: The cTMSs guideline
committee considers the following comments to be appropriate con-
siderations as additional guidance in the application of this
recommendation. This is based on the consensus review of the com-
mitteemembers and input frommembers of the society with applied
TMS clinical experience:
• Extended treatment course: While the peer-reviewed studies
demonstrate that the majority of patients who receive acute
beneﬁt from TMS therapy do sowithin 4–6weeks, it is reasonable
to continue treatment beyond 6 weeks in speciﬁc circum-
stances. For example:
○ In patients who experience only partial improvement and the
clinician believes that a clear plateau of beneﬁt has not been
obtained, it might be appropriate to extend the course of treat-
ment for one or two weeks.
○ For patients who have had no meaningful beneﬁt after 6
weeks, but who have a history of late response to antide-
pressant treatment in prior episodes, have a lengthy duration
of the present episode, or are highly treatment resistant; clin-
ical experience suggests that continuing the course of acute
treatment beyond 6 weeks may be indicated, but with likely
low probability of success.
• These considerations are further justiﬁed by the absence of any
known cumulative toxicity with extended exposure to TMS
[12,19,62,63] and because of open-label data supporting the po-
tential for late response in some patients. In clinical TMS practice
and in one case series [15], there is documented evidence of even-
tual remission at 10 weeks in patients who failed to show any
clinical response at the end of 6 weeks.
Recommendation 2: TMS therapy is recommended for use as
a subsequent option in patients who previously beneﬁted from
an acute treatment course and are experiencing a recurrence of
their illness (continuation or maintenance).
Statement of speciﬁc recommendation for use: TMS therapy
should be considered in patients who present with a clinical
diagnosis consistent with DSM-5 deﬁned Major Depressive Disor-
der, single or recurrent episode, or equivalent nosology and for
whom a prior course of TMS therapy has provided satisfactory
clinical beneﬁt in an earlier episode of their illness. Evidence of
satisfactory clinical beneﬁt should have been veriﬁed with stan-
dardized, validated clinical depression rating scales. Examples of
such scales include the Patient Health Questionnaire, 9-Item Scale
or the Quick Inventory of Depressive Symptoms, Self Report
version. The strongest evidence supports high-frequency treat-
ment over the left DLPFC. Early studies used measurement based
approaches to placing the coil relative to the motor cortex. These
were found to miss the target in about 30% of patients. More
recent studies use placement strategies that adjust for the patient’s
skull size [64]. There are intriguing research leads but no strong
clinical data to suggest that neuronavigation from MRI improves
outcome [65–71]. The standard parameter set described in the
product labeling was studied in three Level 1 randomized con-
trolled trials and has demonstrated clinical beneﬁt in treatment
courses up to six weeks in duration. Controlled studies of longer
duration or using alternative treatment parameters are not clearly
established.
Strength of the recommendation: A, consistent evidence from
Level 1 studies
Principal Supporting Evidence: Level 1b [6–8]
Additional Expert Consensus Comments: The cTMSs Guideline
committee considers the following comments to be clinically ap-
propriate considerations as additional guidance in the application
of this recommendation, based on the consensus review of the
Guideline committee members and input from members of the
Society with applied clinical TMS therapy experience:
• Extended treatment course: (see above following recommen-
dation #1)
Recommendation 3: TMS therapy can be administered with or
without the concomitant administration of antidepressant or
other psychotropic medications.
Statement of speciﬁc recommendation for use: TMS therapy
should be considered in patients who present with a clinical
diagnosis consistent with DSM-5 deﬁned Major Depressive Disor-
der, single or recurrent episode, or equivalent nosology and for
whom antidepressant medication treatment has provided an
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unsatisfactory clinical beneﬁt. TMS therapy should be adminis-
tered in a standard protocol of high frequency, left prefrontal
treatment.
TMS therapy can be administered in the presence or absence of
concurrent antidepressant or other psychotropic medications. There
are currently no data from controlled trials supporting the use of
medications with TMS, but there is currently no evidence of an in-
creased risk of adverse events by combining medications with TMS.
Any change in medications during the course of TMS therapy should
prompt consideration for reassessment of the patient’s motor thresh-
old to ensure that there are no signiﬁcant changes in this parameter.
Strength of the recommendation: B, Extrapolation from Level 2
studies
Principal Supporting Evidence: Carpenter et al. [13] [Level 2b –
individual cohort study]
Additional Expert Consensus Comments: The cTMSs guideline
committee considers the following comments to be appropriate con-
siderations as additional guidance in the application of this
recommendation. A majority of members recommend continuing
extant medications during TMS therapy. Most members refrained
from medication taper during the acute TMS course.
Recommendation 4: TMS therapy can be used as a continua-
tion or maintenance treatment for patients who beneﬁt from
an acute course.
Statement of speciﬁc recommendation for use: TMS therapy can
be considered for intermittent use on an empirical basis as a con-
tinuation treatment for patients who responded to a prior standard
acute course of treatment administered consistent with Recom-
mendations 2 or 3. At the present time, the only controlled trial with
TMS therapy that establishes a speciﬁc continuation regimen is the
Brainsway multi-center trial, which included 12 weeks of biweek-
ly Deep TMS treatment. A majority of cTMSs members use
maintenance medications and psychotherapy, considering contin-
uation ormaintenance TMS therapywhen other establishedmethods
of maintenance antidepressant therapy fail to provide a satisfac-
tory sustained pattern of clinical beneﬁt or a patient has a history
of frequent relapse (two or more in one year). Further consider-
ations in support of continuation or maintenance TMS therapy are
based on current expert consensus opinion and are discussed below.
Strength of the recommendation: A, consistent evidence from
Level 1 studies
Supporting Evidence: Levkovitz et al. [8] [Level 1b studies]
Additional Expert Consensus Comments: The cTMSs guideline
committee considers the following comments clinically appropri-
ate considerations as additional guidance in the application of this
recommendation. In terms of avoiding relapse, themajority of cTMSs
members use maintenance medications and psychotherapy. Some
members consider continuation or maintenance TMS or both when
a patient has a history of frequent relapse (two or more in one year).
cTMSs members reported that they typically administer continu-
ation or maintenance treatments, one session at a time either
monthly, biweekly or weekly; or they titrate the frequency to the
patient’s response.
Recommendation 5: TMS therapy can be reintroduced in pa-
tients who are relapsing into depression after initially responding
to TMS treatment.
Statement of speciﬁc recommendation for use: Should relapse
occur in patients who beneﬁtted from an acute TMS course, it is rec-
ommended that TMS should be reintroduced until remission is re-
achieved. The ﬁrst study that assessed TMS reintroduction involved
the 24-week naturalistic follow-up study [16] that recruited (n = 99)
partial responders to acute TMS (i.e. 25% decrease from the base-
line HAMD17) in the ﬁrst Neuronetics-sponsored multicenter trial
[6]. These patients were tapered off TMS, started on maintenance
antidepressant monotherapy, and followed for a 6-month period.
During this period, 10% (10/99) (Kaplan–Meier survival esti-
mate = 12.9%) of patients relapsed (mean time ~23.5 weeks) and
another 38.4% (38/99) (Kaplan–Meier survival estimate = 40%) pa-
tients met criteria for symptomworsening (at least 1-point decrease
in Clinical Global Impression scale over 2 weeks). The latter group
received adjunctive TMS and 32/38 (84.2%) re-achieved symptom-
atic beneﬁts. The mean time for ﬁrst TMS reintroduction was 109
(±5) days and the mean number of sessions was 14.3 (SD = 9.3). The
more recent study by Phillips found high rates of response in pre-
vious TMS responders or remitters (78% in those getting scheduled
TMS, and 63% in those in the watch and wait group) [37].
Strength of the recommendation: B, Extrapolation from Level 2
studies
Principal Supporting Evidence: Janicak et al. [12] [Level 2b – open
label study]
Additional Expert Consensus Comments: Most (90%) of cTMSs
members reintroduce TMS during early relapse when symptoms
worsen beyond mild severity while only a few (10%) wait until full
relapse occurs. Most cTMSs members provided 3–5 treatments per
week until response or remission is reestablished. The length of TMS
introduction was brief (1–3 weeks) if TMS was reintroduced early
in relapse. Most cTMSsmembers rechecked themotor threshold and
location prior to TMS reintroduction.
Partial and non-responders
In non-responders who have completed four to six weeks of treat-
ment, most cTMSs members terminate treatment after extending
treatment by one to two additional weeks of daily TMS. A smaller
percentage of members ceased treatment immediately after six
weeks. In partial responders who complete the acute phase of six
weeks, most cTMSs members either extend the course but main-
tain the same protocol or extend the course after altering the protocol
(i.e. changing dose and/or location or extending the number of days
between treatments). Most cTMSsmembers do not extend the acute
course beyond six weeks unless the patient is a partial responder
who has not yet achieved maximum beneﬁt.
Remission and tapering
Most cTMSs members (over 90%) surveyed reported that they
typically ﬁrst observe remission in patients between four and six
weeks of treatment. When terminating treatment after remission,
the majority of cTMSs members (78%) taper treatments over three
weeks as was done in the Neuronetics and OPT-TMS trial [6].
Summary and conclusions
Left prefrontal rTMS repeated daily for 4–6 weeks is an effec-
tive and safe treatment in adult patients with unipolar MDD that
have failed one or more antidepressant trials. These conclusions and
guidelines should help the ﬁeld continue to improve and progress.
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